Affivant is a Basel, Switzerland based biotech company, part of the Roivant family. Affivant was established with an in-licensed innate immune cell engager from Affimed. We are currently raising Series A financing, to bring our lead molecule through a phase 1a, first-in-human trial. This is a clinically de-risked program (both technology and target) which is near-to-clinic with high potential for success in commercially attractive cancer indications. Different to other NK cell engagers, ICE (R) molecules bind to multiple innate effector cells. The platform has tetravalent binding which brings significant efficacy advantages, and further engineering limits the risk of ADA and general FcR activation. The potential for innate cell engagers represents a great opportunity in T cell nonresponsive indications such as ovarian cancer. In addition to monotherapy development, we are exploring combination potential for AFVT-2101, including combination with exogenous NK cell products, novel cytokine agonism and immunotherapy.